The overall aim of PPMI is to identify markers of disease progression to accelerate therapeutic trials and reduce the progression of Parkinson’s Disease (PD) disability. The PPMI Prodromal PD cohort is a part of PPMI Clinical, a study conducting in-person clinical and imaging assessments and biosample collection across 50 international sites. The prodromal cohort includes approximately 1,750 participants at risk of developing PD, as of 2024, with plans to recruit 2,750 participants. This includes those with clinical features or biomarkers of PD, and those with a genetic risk of PD. Baseline assessment began in 2011, and participants are followed up every 6 months for at least 5 years.
Study design
Cohort, Cohort - clinical
Number of participants at first data collection
1,750 (participants, as of 2024)
Recruitment is ongoing
Age at first data collection
≥ 60 years (participants with prodromal symptoms)
≥ 30 years (participants with genetic risk)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2011
Primary Institutions
Institute for Neurodegenerative Disorders (INDD)
University of California, San Francisco (UCSF)
Links
ppmi-info.org/study-design/study-cohorts
clinicaltrials.gov/study/NCT04477785
ppmi-info.org/sites/default/files/docs/PPMI%20Data%20User%20Guide.pdf
neurodegenerationresearch.eu/cohort/parkinson%C2%92s-progression-markers-initiative/
Profile paper DOI
Funders
Michael J. Fox Foundation for Parkinson's Research
Ongoing?
Yes
Data types collected
Engagement
Keywords
Consortia and dataset groups